Duska, L., Krasner, C., O'Malley, D., Hays, J., Modesitt, S., Mathews, C., . . . Schilder, R. (2021). A phase Ib/II and pharmacokinetic study of EP0057 (formerly CRLX101) in combination with weekly paclitaxel in patients with recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancer. Gynecologic Oncology, 160(3), 688. https://doi.org/10.1016/j.ygyno.2020.12.025
Chicago-referens (17:e uppl.)Duska, L.R, et al. "A Phase Ib/II and Pharmacokinetic Study of EP0057 (formerly CRLX101) in Combination with Weekly Paclitaxel in Patients with Recurrent or Persistent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer." Gynecologic Oncology 160, no. 3 (2021): 688. https://doi.org/10.1016/j.ygyno.2020.12.025.
MLA-referens (9:e uppl.)Duska, L.R, et al. "A Phase Ib/II and Pharmacokinetic Study of EP0057 (formerly CRLX101) in Combination with Weekly Paclitaxel in Patients with Recurrent or Persistent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer." Gynecologic Oncology, vol. 160, no. 3, 2021, p. 688, https://doi.org/10.1016/j.ygyno.2020.12.025.
